Cargando…

Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors

Molibresib (GSK525762) is an investigational orally bioavailable small‐molecule bromodomain and extraterminal (BET) protein inhibitor for the treatment of advanced solid tumors. In the first‐time‐in‐human BET115521 study of molibresib in patients with solid tumors, thrombocytopenia was the most freq...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krishnatry, Anu Shilpa, Hanze, Eva, Bergsma, Tim, Dhar, Arindam, Prohn, Marita, Ferron‐Brady, Geraldine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124358/ https://www.ncbi.nlm.nih.gov/pubmed/34648693 http://dx.doi.org/10.1002/psp4.12724

Ejemplares similares

Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model
por: Krishnatry, Anu Shilpa, et al.
Publicado: (2021)

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
por: Dawson, Mark A., et al.
Publicado: (2023)

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors
por: Piha-Paul, Sarina A, et al.
Publicado: (2019)

An Adaptive Physiologically Based Pharmacokinetic–Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers
por: Riddell, Kylie, et al.
Publicado: (2020)

Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor
por: Joshi, Samit R., et al.
Publicado: (2020)

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors
por: Ferron, Géraldine M., et al.
Publicado: (2013)

622. Population Pharmacokinetic Analysis and Probability of Target Attainment Simulations of Pivmecillinam for the Treatment of Uncomplicated Urinary Tract Infection
por: Santerre Henriksen, Anne Laurence, et al.
Publicado: (2022)

Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes
por: Regan, Jessica A., et al.
Publicado: (2023)

Emotional neglect and parents’ adverse childhood events
por: Ylitervo, Laura, et al.
Publicado: (2023)

Population pharmacokinetics and exposure–response of anti‐programmed cell death protein‐1 monoclonal antibody dostarlimab in advanced solid tumours
por: Melhem, Murad, et al.
Publicado: (2022)

Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis
por: Chan, Phyllis, et al.
Publicado: (2020)

Impact of Plasma Exposure of Statins and Their Metabolites With Major Adverse Cardiovascular Events in Chinese Patients With Coronary Artery Disease
por: Zhou, Xiao-hong, et al.
Publicado: (2020)

Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study
por: Jagt, Jasmijn Z., et al.
Publicado: (2021)

Elevated Ratio of Urinary Metabolites of Thromboxane and Prostacyclin Is Associated with Adverse Cardiovascular Events in ADAPT
por: Montine, Thomas J., et al.
Publicado: (2010)

Patient stratification and identification of adverse event correlations in the space of 1190 drug related adverse events
por: Roitmann, Eva, et al.
Publicado: (2014)

Exposure–Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma
por: Ferron‐Brady, Geraldine, et al.
Publicado: (2021)

Identifying Patterns of Adverse Events of Solid Organ Transplantation Through Departmental Case Reviews
por: Mathur, Amit K., et al.
Publicado: (2019)

Tryptophan metabolites suppress the Wnt pathway and promote adverse limb events in chronic kidney disease
por: Arinze, Nkiruka V., et al.
Publicado: (2022)

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
por: Gupta, Neeraj, et al.
Publicado: (2020)

Plasma Gut Microbe-Derived Metabolites Associated with Peripheral Artery Disease and Major Adverse Cardiac Events
por: Ho, Karen J., et al.
Publicado: (2022)

PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study
por: Huang, Guili, et al.
Publicado: (2022)

Colored Corn: An Up-Date on Metabolites Extraction, Health Implication, and Potential Use
por: Colombo, Raffaella, et al.
Publicado: (2021)

Traffic safety knowledge gain of ambulance drivers after simulator-based training
por: Prohn, Maria J., et al.
Publicado: (2022)

Potentially Critical Driving Situations During “Blue-light” Driving: A Video Analysis
por: Prohn, Maria J., et al.
Publicado: (2023)

Genetic Polymorphisms and Adverse Events on Unbound Imatinib and Its Active Metabolite Concentration in Patients With Gastrointestinal Stromal Tumors
por: Qian, Yi, et al.
Publicado: (2019)

Model‐Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti–PD‐1 Monoclonal Antibody in Advanced Solid Tumors
por: Ahamadi, M, et al.
Publicado: (2016)

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
por: Rathi, Chetan, et al.
Publicado: (2021)

Solid-Phase Extraction Embedded Dialysis (SPEED), an Innovative Procedure for the Investigation of Microbial Specialized Metabolites
por: Mai, Phuong-Y., et al.
Publicado: (2021)

Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events
por: Yu, Yue, et al.
Publicado: (2016)

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)—estimation of adverse event risks
por: Stegherr, Regina, et al.
Publicado: (2021)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

Basic techniques in endoscopic ultrasound-guided fine needle aspiration for solid lesions: Adverse events and avoiding them
por: Fujii, Larissa L., et al.
Publicado: (2014)

Factors Predictive of Adverse Events Associated with Endoscopic Ultrasound-Guided Fine Needle Aspiration of Pancreatic Solid Lesions
por: Katanuma, Akio, et al.
Publicado: (2013)

Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials
por: Yin, Xiaonan, et al.
Publicado: (2018)

Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors
por: Shimozaki, Keitaro, et al.
Publicado: (2020)

Gastroparesis as a significant gastrointestinal adverse event during intensive chemotherapy for solid caner: a case report
por: Nakayama, Tomohiro, et al.
Publicado: (2022)

Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy
por: Dora, David, et al.
Publicado: (2023)

Categorisation of Pharmaceutical Adverse Events Using the Japanese Adverse Drug Event Report Database: Characteristic Adverse Drug Events of the Elderly Treated with Polypharmacy
por: Negishi, Akio, et al.
Publicado: (2020)

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
por: Kato, Yamato, et al.
Publicado: (2015)

Adverse Events of Antiepileptic Drugs Using Indonesian Version of Liverpool Adverse Events Profile
por: Budikayanti, Astri, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lsggfcmiai71o6lqessueeaq16